RhumbLine Advisers
LBRX

RhumbLine Advisers’s LB Pharmaceuticals LBRX Stock Holding History

RhumbLine Advisers’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902K Buy
27,789
+10,686
+62% +$314K ﹤0.01% 2379
2026
Q1 		$422K Buy
17,103
+820
+5% +$18.9K ﹤0.01% 2715
2025
Q4 		$362K Buy
+16,283
New +$284K ﹤0.01% 2865

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

RhumbLine Advisers's LBRX Position: Q2 2026 in Review

RhumbLine Advisers increased its LB Pharmaceuticals (LBRX) stake by 62% in Q2 2026, buying an estimated $314K and bringing the position to 27,789 shares worth $902K. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

RhumbLine Advisers first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • RhumbLine Advisers held 27,789 shares of LB Pharmaceuticals worth $902K as of Q2 2026.
  • RhumbLine Advisers bought 10,686 LB Pharmaceuticals shares in Q2 2026, an estimated $314K.
  • LB Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2379 holding.
  • RhumbLine Advisers first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.